LBRX - LB Pharmaceuticals Inc Common Stock
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
As of Jul 15, 2026: spot at $31.75, ATM IV 91.2%, max pain $22.50, net GEX $1.5K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $922.2M
- Beta
- 0.56
- 52-Week Range
- 13.36-35.345
- CEO
- Heather D. Turner
- Employees
- 27
- IPO Date
- Sep 11, 2025
- Exchange
- NASDAQ
What LBRX Looks Like to Options Traders Today
positive net gamma exposure ($1.5K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-0.171) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The LBRX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked LBRX overview questions
- What is LBRX?
- LBRX is the ticker symbol for LB Pharmaceuticals Inc Common Stock, a listed security. This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride. Listed on NASDAQ. LBRX is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the LBRX options snapshot look like today?
- As of Jul 15, 2026, the LBRX options snapshot shows spot at $31.75, ATM IV 91.2%, max pain $22.50, net GEX $1.5K, expected move 26.15%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are LBRX's key statistics?
- LB Pharmaceuticals Inc Common Stock (LBRX) carries a market capitalization of $922.2M, beta of 0.56 relative to the broader market, 52-week range of 13.36-35.345. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does LBRX belong to?
- LB Pharmaceuticals Inc Common Stock operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare LBRX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the LBRX data on this page?
- The options snapshot above is dated Jul 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).